Download PDF
Thromb Haemost 1985; 53(01): 141-142
DOI: 10.1055/s-0038-1661255
Original Article
Schattauer GmbH Stuttgart

Effects of Oral Stanozolol Used in the Prevention of Postoperative Deep Vein Thrombosis on Fibrinolytic Activity

H M Sue-Ling
The University Departments of Medicine and Surgery, The General Infirmary, Leeds, England
,
J A Davies
The University Departments of Medicine and Surgery, The General Infirmary, Leeds, England
,
C R M Prentice
The University Departments of Medicine and Surgery, The General Infirmary, Leeds, England
,
J H Verheijen
*   The University Hospital and Gaubius Institute TNO, Leiden, The Netherlands
,
C Kluft
*   The University Hospital and Gaubius Institute TNO, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 02 August 1984

Accepted 13 December 1984

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Plasminogen, fibrinogen, antithrombin III, euglobulin lysis time, tissue plasminogen activator (t-PA) and fast-acting t-PA inhibitor were measured in 21 patients receiving either stanozolol (10 mg orally given for 14 days preoperatively) or subcutaneous heparin, during a continuing comparative trial in the prevention of postoperative deep vein thrombosis.

Stanozolol treatment resulted in significant (p <0.01) increases between the 14th and 1st preoperative days in the plasma concentrations of plasminogen (3.4 to 4.9 Cu/ml) and antithrombin III (107% to 132%); t-PA levels did not increase significantly (6.0 to 16.0 mU/ml; p >0.1). There were significant (p <0.02) falls in fast-acting t-PA inhibitor (132% to 75%) and fibrinogen (2.4 to 1.8 g/1).

Surgery reversed the changes in fibrinolytic activity seen preoperatively in the stanozolol-treated patients, and similar changes were seen in the heparin-treated group. In this dosage, stanozolol does not appear to prevent the fibrinolytic shutdown which occurs after elective major surgery.

Key words

Stanozolol - Fibrinolytic activity - Deep vein thrombosis
 

  • References

  • 1 Negus D, Pinto DJ, LeQuesne LP, Brown N, Chapman M. 125I-labelled fibrinogen in the diagnosis of deep vein thrombosis and its correlation with phlebography. Br J Surg 1968; 55: 835-839
    CrossrefPubMedGoogle Scholar
  • 2 Kakkar VV, Flanc C, Howe CT, Clarke MB. Natural history of postoperative deep vein thrombosis. Lancet 1969; 2: 230-233
    PubMedGoogle Scholar
  • 3 MacIntyre IM C, Webber RG, Crispin JR, Jones DR B, Wood JK, Allan NC, Prescott RJ, Ruckley CV. Plasma fibrinolysis and postoperative deep vein thrombosis. Br J Surg 1976; 63: 694-697
    CrossrefPubMedGoogle Scholar
  • 4 Gordon-Smith IC, Hickman JA, Le Quesne LP. Postoperative fibrinolytic activity and deep vein thrombosis. Br J Surg 1974; 61: 231-238
    PubMedGoogle Scholar
  • 5 Mansfield AO. Alterations in fibrinolysis associated with surgery and venous thrombosis. Br J Surg 1972; 59: 754-757
    CrossrefPubMedGoogle Scholar
  • 6 Knight MT N, Dawson R. Effect of intermittent compression of the arms on deep vein thrombosis in the legs. Lancet 1976; 2: 1265-1268
    PubMedGoogle Scholar
  • 7 Blarney SL, McArdle BM, Burns P, Lowe GD O, Forbes CD, Carter DC, Prentice CR M. Prevention of fibrinolytic shutdown after major surgery by intramuscular stanozolol. Thromb Res 1983; 31: 451-459
    CrossrefPubMedGoogle Scholar
  • 8 Clayton JK, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. Br Med J 1976; 2: 910-912
    CrossrefPubMedGoogle Scholar
  • 9 Blix S. Studies on the fibrinolytic system in the euglobulin fraction of human plasma. Scand J Clin Lab Invest 1961; 13 suppl (Suppl. 58) 3-19
    PubMedGoogle Scholar
  • 10 Ratnoff OD, Menzies C. A new method for determination of fibrinogen in small samples of plasma. J Lab Clin Med 1951; 37: 316-320
    PubMedGoogle Scholar
  • 11 Verheijen JH, Mullaart E, Chang GT G, Kluft C, Wijngaards GA. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 12 Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and chromozym TH). Thromb Res 1977; 11: 549-553
    CrossrefPubMedGoogle Scholar
  • 13 Alkjaersig N, Fletcher AP, Sherry S. The mechanism of clot dissolution by plasmin. J Clin Invest 1959; 38: 1086-1095
    CrossrefPubMedGoogle Scholar
  • 14 Verheijen JH, Rijken DC, Brommer EJ P, Chang GT G. Measurement of tissue-type plasminogen activator activity, antigen and inhibition in plasma. In: Jespersen J, Kluft C, Korsgaard O. (Eds) Clinical Aspects of Fibrinolysis and Thrombolysis. South Jutland University Press; Esbjerg, Denmark: 1983. pp 121-131
    Google Scholar
  • 15 Preston FE, Burakowski BK, Porters NR, Malia RG. The fibrinolytic response to stanozolol in normal subjects. Thromb Res 1981; 22: 543-551
    CrossrefPubMedGoogle Scholar
  • 16 Sue-Ling HM, Davies JA, Prentice CR M, Bertina RM, Verheijen JH, Kluft C. Changes in fibrinolytic activity in patients receiving prophylaxis with stanozolol for postoperative DVT. Haemostasis 1984; 14: 32 (Abstr.)
    PubMedGoogle Scholar
  • 17 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fastacting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
    PubMedGoogle Scholar
  • 18 Verheijen JH, Rijken DC, Chang GT G, Preston FE, Kluft C. Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol. Thromb Haemos-tas 1984; 51: 396-397
    PubMedGoogle Scholar